FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocar... von Sahin, U., Türeci, Ö., Manikhas, G., Lordick, F., Rusyn, A., Vynnychenko, I., Dudov, A., Bazin, I., Bondarenko, I., Melichar, B., Dhaene, K., Wiechen, K., Huber, C., Maurus, D., Arozullah, A., Park, J.W., Schuler, M., Al-Batran, S.-E.

Volltext

A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer von Reppert, S., Boross, I., Koslowski, M., Türeci, Ö., Koch, S., Lehr, H.A., Finotto, S.

Volltext

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study von Türeci, O., Sahin, U., Schulze-Bergkamen, H., Zvirbule, Z., Lordick, F., Koeberle, D., Thuss-Patience, P., Ettrich, T., Arnold, D., Bassermann, F., Al-Batran, S.E., Wiechen, K., Dhaene, K., Maurus, D., Gold, M., Huber, C., Krivoshik, A., Arozullah, A., Park, J.W., Schuler, M.

Volltext

Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside von Boisguérin, V, Castle, J C, Loewer, M, Diekmann, J, Mueller, F, Britten, C M, Kreiter, S, Türeci, Ö, Sahin, U

Volltext

1196TiP LuCa-MERIT-1: First-in-human, open label, phase I dose confirmation trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations... von Forde, P.M., Atmaca, A., Brück, P., Munshi, N., Kaczorowska, M.A., Schell, T., Türeci, Ö., Sahin, U.

Volltext

Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo von Kuhn, A N, Diken, M, Kreiter, S, Selmi, A, Kowalska, J, Jemielity, J, Darzynkiewicz, E, Huber, C, Türeci, Ö, Sahin, U

Volltext

658PPatient reported outcomes (PRO) results from phase II MONO and FAST zolbetuximab (IMAB362) trials in patients with advanced CLDN18.2+ gastric and gastroesophageal junction aden... von Morlock, R, Krukas-Hampel, M R, Türeci, Ö

Volltext

999MO HARE-40: A phase I/II trial of therapeutic HPV vaccine (BNT113) in patients with HPV16 driven carcinoma von Ottensmeier, C.H.H., King, E., Crabb, S., Karydis, I., Graham, D.M., Martin, K., Eberhart, I., Ewings, S., Lee, P., McCann, K., Chudley, L., Berry, L., Dias, J., Das, R., Furlanetto, J., Johnson, E., Setzer, J., Sahin, U., Türeci, Ö., Griffiths, G.

Volltext

Patient reported outcomes (PRO) results from phase II MONO and FAST zolbetuximab (IMAB362) trials in patients with advanced CLDN18.2+ gastric and gastroesophageal junction adenocar... von Morlock, R., Krukas-Hampel, M.R., Türeci, Ö

Volltext

Preclinical characterization of IMAB362-vcMMAE, an anti-CLDN18.2 antibody–drug conjugate von Kreuzberg, M., Mitnacht-Kraus, R., Sahin, U., Türeci, Ö.

Volltext

LBA35 BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR-T cells manufactured with an automated process ± a CLDN6-encoding CAR-T cell-amplifying RNA Vaccin... von Mackensen, A., Haanen, J.B.A.G., Alsdorf, W., Koenecke, C., Wagner-Drouet, E., Borchmann, P., Heudobler, D., Busse, A., Klobuch, S., Kutsch, N., Müller, F., Bokemeyer, C., Desuki, A., Lueke, F., Ho, T., Vemuri, K., Preussner, L., Rengstl, B., Türeci, Ö., Sahin, U.

Volltext

1072P DuoBody-EpCAMx4-1BB mediates conditional T cell co-stimulation and promotes antitumor activity in preclinical models von Fellermeier-Kopf, S., Ioan-Facsinay, A., Imle, A., Diks, A.M., Nuermberger, K.B., Guelen, L., Köhne, M., Houtkamp, M., Toker, A., Burm, S.M., Gamse, J., Janaitis, C., Satijn, D., Muik, A., Ahmadi, T., Türeci, Ö., Kemper, K., Sahin, U., Breij, E.

Volltext

611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine i... von Haanen, J.B.A.G., Mackensen, A., Schultze-Florey, C., Alsdorf, W., Wagner-Drouet, E., Heudobler, D., Borchmann, P., Busse, A., Mielke, S., Bins, S., Ungerechts, G., Bokemeyer, C., Klobuch, S., Kutsch, N., Müller, F., Desuki, A., Zhong, W., Preussner, L., Türeci, Ö., Sahin, U.

Volltext

877P Exploratory efficacy and translational results from the safety run in of AHEAD-MERIT, a phase II trial of first line pembrolizumab plus the fixed-antigen cancer vaccine BNT113... von Saba, N.F., Klinghammer, K., Castelluci, E., Colevas, A.D., Rutkowski, T., Thurner, D., Müller-Richter, U., Maio, M., Grewal, J.S., Ottensmeier, C.H.H., Dias, J., Yang, H., Das, R., Furlanetto, J., Herzfeldt, A-K., Kühnle, M-C., Ulges, A., Alles, J., Türeci, Ö., Sahin, U.

Volltext

29P Characterization of T cell responses induced by the individualized mRNA neoantigen vaccine autogene cevumeran in adjuvant stage II (high risk)/stage III colorectal cancer (CRC)... von Elez Fernandez, M.E., Maurel, J., Morris, V., Kopetz, S., Galligan, B., Ali, S., Derhovanessian, E., Unsal-Kacmaz, K., Manning, L., Henn, H., Weisenburger, T., Tonigold, M., Zurek, P., Fierek-Ulbig, M., Cortini, A., Pino Claveria, M., Preussner, L., Mueller, F., Türeci, Ö., Sahin, U.

Volltext

Tumor-associated CpG demethylation augments hypoxia-induced effects by positive autoregulation of HIF-1α von Koslowski, M, Luxemburger, U, Türeci, Ö, Sahin, U

Volltext

Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation von Diken, M, Kreiter, S, Selmi, A, Britten, C M, Huber, C, Türeci, Ö, Sahin, U

Volltext

LBA1 BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+ advanced solid tumors von Haanen, J., Mackensen, A., Koenecke, C., Alsdorf, W., Desuki, A., Wagner-Drouet, E., Heudobler, D., Borchmann, P., Wiegert, E., Schulz, C., Rengstl, B., Preußner, L., Türeci, Ö., Sahin, U.

Volltext

1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccin... von Thomas, S.J., Perez, J.L., Lockhart, S.P., Hariharan, S., Kitchin, N., Bailey, R., Liau, K., Lagkadinou, E., Türeci, Ö., Şahin, U., Xu, X., Dychter, S.S., Lu, C., Gentile, T., Gruber, W.

Volltext

Autoantibodies in lung cancer: possibilities for early detection and subsequent cure von Chapman, C J, Murray, A, McElveen, J E, Sahin, U, Luxemburger, U, Türeci, Ö, Wiewrodt, R, Barnes, A C, Robertson, J F

Volltext